ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Ra Capital Management, L.P. purchased 3,750,000 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was purchased at an average price of $6.20 per share, for a total transaction of $23,250,000.00. Following the completion of the acquisition, the director now owns 5,856,774 shares of the company’s stock, valued at $36,311,998.80. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
ARS Pharmaceuticals Trading Up 0.3 %
Shares of SPRY stock opened at $7.11 on Friday. The firm’s fifty day moving average price is $6.88 and its two-hundred day moving average price is $7.09. ARS Pharmaceuticals, Inc. has a 1 year low of $3.99 and a 1 year high of $9.65.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $0.01 million during the quarter. On average, equities research analysts predict that ARS Pharmaceuticals, Inc. will post -0.81 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Separately, Wedbush reissued an “outperform” rating and issued a $15.00 target price on shares of ARS Pharmaceuticals in a research report on Monday, August 14th.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis.
- Five stocks we like better than ARS Pharmaceuticals
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- What Are Growth Stocks and Investing in Them
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.